Kymera Therapeutics (KYMR) Change in Cash (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Change in Cash data on file, last reported at -$212.9 million in Q1 2026.

• Change in Cash for Q1 2026 came in at -$212.9 million, down 603.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.1 million (up 1619.57% YoY), and the FY2025 annual result was $236.8 million, up 2204.69% from the prior year.
• Change in Cash declined to -$212.9 million in Q1 2026 per KYMR's latest filing, from $244.1 million in the prior quarter.
• Over five years, Change in Cash peaked at $245.9 million in Q2 2025 and troughed at -$222.9 million in Q3 2025.
• A 5-year average of $5.6 million and a median of $1.9 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2024 and 2025: Change in Cash slumped 1470.87% in 2024, then jumped 2456.02% in 2025.
• A 5-year view of Change in Cash shows it stood at -$87.2 million in 2022, then soared by 133.16% to $28.9 million in 2023, then sank by 66.99% to $9.5 million in 2024, then jumped by 2456.02% to $244.1 million in 2025, then plunged by 187.23% to -$212.9 million in 2026.
• Business Quant data shows KYMR's Change in Cash at -$212.9 million in Q1 2026, $244.1 million in Q4 2025, and -$222.9 million in Q3 2025.